Pharma firm Moderna is set to test the world's first vaccine against norovirus, a highly contagious vomiting bug. The virus reportedly causes around 12K hospitalities in the UK alone — and 685M cases of gastroenteritis globally — each year, especially in winters.
Norovirus, or the winter vomiting bug, spreads via contact with infected persons or through contaminated surfaces or food and water. Its symptoms are nausea, projectile vomiting, diarrhea, high temperature, severe abdominal pain, and aching limbs. It affects people of all ages.
Moderna's mRNA technology-based jab reportedly targets three major strains norovirus, a disease that can currently be treated only with intravenous fluids in severe cases. British Health Secretary Wes Streeting says it costs "taxpayers around £100M (nearly $130M) a year."
TheA suddennorovirus surgevaccine will mark a crucial breakthrough. Norovirus's ability to spread rapidly in norovirusclose casesquarters ismakes it a serious public health concern. TheWith rapidno spreadcurrent throughtreatment schools and careprevention homesreliant putson vulnerablehygiene, populationsa atvaccine risk.would Immediatebe actiona isgame-changer, neededpotentially toreducing preventthe aburden potentialof widespreadoutbreaks outbreakand thatpreventing couldsevere overwhelm healthcare facilitiescases.
The increase in norovirus cases is a natural consequence of returning to normal social interactions after the covid-era cloistering. The human immune system needs exposure to common viruses to maintain strength. OverreactingWhile a vaccine is always welcome, overreacting to thisa situation could lead to unnecessary panic and disruption of daily life.